Details of the Drug Reposition

General Information of This Drug (ID: DMUOK4C)

• Drug Name: Lisinopril (DMUOK4C)
• Synonyms: Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

3 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypertension	DISLL965	BA00-BA04	Approved	[1]
Myocardial infarction	DIS655KI	BA41-BA43	Approved	[2]
Chronic heart failure	DISD18PM	BD1Z	Approved	[2]

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Investigative	[3]
High blood pressure	DISY2OHH	BA00	Investigative	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Lisinopril FDA Label
• [3] Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.